Skip to main content

Rate Control in Atrial Fibrillation

Choice of Treatment and Assessment of Efficacy

Drugs volume 63, pages 1489–1509 (2003)Cite this article

Abstract

The clinical relevance and high social costs of atrial fibrillation have boosted interest in rate control as a cost-effective alternative to long-term maintenance of sinus rhythm (i.e. rhythm control). Prospective studies show that rate control (coupled with thromboembolic prophylaxis) is a valuable treatment option for all forms of atrial fibrillation. The rationale for rate control is that high ventricular rates, frequently found in atrial fibrillation, lead to haemodynamic impairment, consisting of a variable combination of loss of atrial kick, irregularity in ventricular response and inappropriately rapid ventricular rate, depending on the type of underlying heart disease. Long-term persistence of tachycardia at a high ventricular rate can lead to various degrees of ventricular dysfunction and even to tachycardiomyopathy-related heart failure. Identification of this reversible and often concealed form of left ventricular dysfunction can permit effective management by rate (or rhythm) control.

Although acute rate control (to reduce ventricular rate within hours) is still often based on digoxin administration, for patients without left ventricular dysfunction, calcium channel antagonists or β-adrenoceptor antagonists (β-blockers) are generally more appropriate and effective. In chronic atrial fibrillation, longterm rate control (to reduce morbidity/mortality and improve quality of life) must be adapted to patients' individual characteristics to grant control during daily activities, including exercise. According to current guidelines, the clinical target of rate control should be a ventricular rate below 80–90 bpm at rest. However, in many patients, assessment of the appropriateness of different drugs should include exercise testing and 24h-Holter monitoring, for which specific guidelines are needed.

In practice, rate control is considered a valid alternative to rhythm control. Recent prospective trials (e.g. the Pharmacological Intervention in Atrial Fibrillation [PIAF] and the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] trials) have shown that in selected patients, rate control provides similar benefits, more economically, in terms of quality of life and long-term mortality.

The choice of a rate control medication (digoxin, β-blockers, calcium channel antagonists or possibly amiodarone) or a non-pharmacological approach (mainly atrioventricular node ablation coupled with pacing) must currently be based on clinical assessment, which includes assessing the presence of underlying heart disease and haemodynamic impairment. Definite guidelines are required for each different subset of patients. Rate control is particularly tricky in patients with heart failure, for whom non-pharmacological options can also be considered. The preferred pharmacological options are β-blockers for stabilised heart failure and digoxin for unstabilised forms.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III
Fig. 1
Table IV
Fig. 2
Table V
Fig. 3
Table VI
Fig. 4
Table VII

References

  1. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82 (1 Suppl.): 2N–9N

    PubMed  Article  CAS  Google Scholar 

  2. Murgatroid FD, Camm AJ. Atrial arrhythmias. Lancet 1993; 341: 1317–22

    Article  Google Scholar 

  3. Waktare JE, Camm AJ. Acute treatment of atrial fibrillation: why and when to maintain sinus rhythm. Am J Cardiol 1998; 81 (5 Suppl. A): 3C–15C

    PubMed  Article  CAS  Google Scholar 

  4. Gallagher MM, Camm J. Classification of atrial fibrillation. Am J Cardiol 1998; 82 (8 Suppl. A): 18N–28N

    PubMed  Article  CAS  Google Scholar 

  5. Falk R. Farmacologic control of the ventricular rate in atrial fibrillation. In: Falk R, Hodrid P, editors. Atrial fibrillation mechanism and management. Philadelphia (PA): Lippincott-Raven, 1997: 299–327

    Google Scholar 

  6. Rawles JM. What is meant by a ‘controlled’ ventricular rate in atrial fibrillation? Br Heart J 1990; 63(3): 157–61

    PubMed  Article  CAS  Google Scholar 

  7. Murgatroyd FD, Xie B, Gibson SM, et al. The effects of digoxin in patients with paroxismal atrial fibrillation: analysis of Holter data from the CRAFT-1 trial [abstract]. J Am Coll Cardiol 1993; 21 Suppl. A: 203A

    Google Scholar 

  8. Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. BMJ (Clin Res Ed) 1985; 290(6461): 9–11

    Article  CAS  Google Scholar 

  9. Schumacher B, Luderitz B. Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control. Am J Cardiol 1998; 82 (8 Suppl. A): 29N–36N

    PubMed  Article  CAS  Google Scholar 

  10. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive Summary a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001; 104(17): 2118–50

    PubMed  CAS  Google Scholar 

  11. Roberts SA, Diaz C, Nolan PE, et al. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol 1993; 72(7): 567–73

    PubMed  Article  CAS  Google Scholar 

  12. Sarter BH, Marchlinski FE. Redefining the role of digoxin in the treatment of atrial fibrillation. Am J Cardiol 1992; 69 Suppl. 18: 71G-8G

    Article  Google Scholar 

  13. McAlister FA, Ackman ML, Tsuyuki RT, et al. Contemporary utilization of digoxin in patients with atrial fibrillation: Clinical Quality Improvement Network Investigators. Ann Pharmacother 1999; 33(3): 289–93

    PubMed  Article  CAS  Google Scholar 

  14. Goldenberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994; 74(9): 884–9

    PubMed  Article  CAS  Google Scholar 

  15. Boriani G, Biffi M, Capucci A, et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol 1998; 21(11 Pt 2): 2470–4

    PubMed  Article  CAS  Google Scholar 

  16. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1996; 27(5): 1079–82

    PubMed  Article  CAS  Google Scholar 

  17. Clemo HF, Wood MA, Gilligan DM, et al. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998; 81(5): 594–8

    PubMed  Article  CAS  Google Scholar 

  18. Silverman DI, Manning WJ. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation 1998; 98(5): 479–86

    PubMed  Article  CAS  Google Scholar 

  19. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000; 49(1): 47–59

    PubMed  CAS  Google Scholar 

  20. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33(2): 304–10

    PubMed  Article  CAS  Google Scholar 

  21. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16(1): 86–90

    PubMed  Article  CAS  Google Scholar 

  22. Corbelli R, Masterson M, Wilkoff BL. Chronotropic response to exercise in patients with atrial fibrillation. Pacing Clin Electrophysiol 1990; 13(2): 179–87

    PubMed  Article  CAS  Google Scholar 

  23. Raeder EA. Circadian fluctuations in ventricular response to atrial fibrillation. Am J Cardiol 1990; 66(12): 1013–6

    PubMed  Article  CAS  Google Scholar 

  24. Theisen K, Haufe M, Peters J, et al. Effect of the calcium antagonist diltiazem on atrioventricular conduction in chronic atrial fibrillation. Am J Cardiol 1985; 55(1): 98–102

    PubMed  Article  CAS  Google Scholar 

  25. Channer KS, Papouchado M, James MA, et al. Towards improved control of atrial fibrillation. Eur Heart J 1987; 8(2): 141–7

    PubMed  CAS  Google Scholar 

  26. Hnatkova K, Murgatroyd FD, Camm AJ,et al. Effect of digoxin on the ventricular rate variability during paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 1996; 19(11 Pt 2): 1968–71

    PubMed  Article  CAS  Google Scholar 

  27. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98(23): 2574–9

    CAS  Google Scholar 

  28. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30(3): 791–8

    PubMed  Article  CAS  Google Scholar 

  29. Jessurun GA, Boersma WG, Crijns HJ. Amiodarone-induced pulmonary toxicity: predisposing factors, clinical symptoms and treatment. Drug Saf 1998; 18(5): 339–44

    PubMed  Article  CAS  Google Scholar 

  30. Counihan PJ, McKenna WJ. Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias. Drug Saf 1990; 5(4): 286–304

    PubMed  Article  CAS  Google Scholar 

  31. Hayano J, Sakata S, Okada A, et al. Circadian rhythms of atrioventricular conduction properties in chronic atrial fibrillation with and without heart failure. J Am Coll Cardiol 1998; 31(1): 158–66

    PubMed  Article  CAS  Google Scholar 

  32. Crijns H, Van Gelder IC, Tieleman RG, et al. Atrial fibrillation: antiarrhythmic therapy. In: Yusuf S, Cairns JA, Camm AJ, et al., editors. Evidence based cardiology. London: BMJ Books, 1998: 527–43

    Google Scholar 

  33. Atrial fibrillation follow-up investigation of rhythm management: the AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Am J Cardiol 1997; 79(9): 1198–202

    Article  Google Scholar 

  34. Levy S, Breithardt G, Campbell RW, et al. Atrial fibrillation: current knowledge and recommendations for management: Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998; 19(9): 1294–320

    PubMed  Article  CAS  Google Scholar 

  35. Naccarelli GV. An update on atrial fibrillation: a report from the Annual American Heart Association Session; 2000 Nov 12–15; New Orleans (LA)

  36. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997; 30(4): 1104–6

    PubMed  Article  CAS  Google Scholar 

  37. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999; 1 Suppl. H: H64–9

    Google Scholar 

  38. Wasmer K, Oral H, Sticherling C, et al. Assessment of ventricular rate in patients with chronic atrial fibrillation [abstract]. J Am Coll Cardiol 2001; 37 (2 Suppl. A): 93A

    Article  Google Scholar 

  39. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med 1988; 85(2): 242–4

    PubMed  Article  CAS  Google Scholar 

  40. Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69(19): 1570–3

    PubMed  Article  CAS  Google Scholar 

  41. Rodriguez LM, Smeets JL, Xie B, et al. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993; 72(15): 1137–41

    PubMed  Article  CAS  Google Scholar 

  42. Edner M, Caidahl K, Bergfeldt L, et al. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J 1995; 74(3): 261–7

    PubMed  Article  CAS  Google Scholar 

  43. Gallagher JJ. Tachycardia and cardiomyopathy: the chicken-egg dilemma revisited. J Am Coll Cardiol 1985; 6(5): 1172–3

    PubMed  Article  CAS  Google Scholar 

  44. Van den Berg MP, Tuinenburg AE, Crijns HJ, et al. Heart failure and atrial fibrillation: current concepts and controversies. Heart 1997; 77(4): 309–13

    PubMed  Google Scholar 

  45. Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996; 78(12): 1433–6

    PubMed  Article  CAS  Google Scholar 

  46. Clark DM, Plumb VJ, Epstein AE, et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30(4): 1039–45

    PubMed  Article  CAS  Google Scholar 

  47. Ueng KC, Tsai TP, Tsai CF, et al. Acute and long-term effects of atrioventricular junction ablation and WIR pacemaker in symptomatic patients with chronic lone atrial fibrillation and normal ventricular response. J Cardiovasc Electrophysiol 2001; 12(3): 303–9

    PubMed  Article  CAS  Google Scholar 

  48. Geelen P, Goethals M, de Bruyne B, et al. A prospective hemodynamic evaluation of patients with chronic atrial fibrillation undergoing radiofrequency catheter ablation of the atrioventricular junction. Am J Cardiol 1997; 80(12): 1606–9

    PubMed  Article  CAS  Google Scholar 

  49. Brown CS, Mills Jr RM, Conti JB, et al. Clinical improvement after atrioventricular nodal ablation for atrial fibrillation does not correlate with improved ejection fraction. Am J Cardiol 1997; 80(8): 1090–1

    PubMed  Article  CAS  Google Scholar 

  50. Dupuis JM, Victor J, Le Davay M, et al. Results of radiofrequency ablation of the atrioventricular junction in patients with refractory atrial arrhythmia and severe impairment of the left ventricular systolic function. Arch Mal Coeur Vaiss 1997; 90(9): 1255–62

    PubMed  CAS  Google Scholar 

  51. Twidale N, Manda V, Nave K, et al. Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure. Am Heart J 1998; 136(4 Pt 1): 647–57

    PubMed  Article  CAS  Google Scholar 

  52. Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000; 75(8): 790–5

    PubMed  Article  CAS  Google Scholar 

  53. Fenelon G, Wijns W, Andries E, et al. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol 1996; 19(1): 95–106

    PubMed  Article  CAS  Google Scholar 

  54. Chew PH, Bush DE, Engel BT, et al. Overnight heart rate and cardiac function in patients with dual chamber pacemakers. Pacing Clin Electrophysiol 1996; 19(5): 822–8

    PubMed  Article  CAS  Google Scholar 

  55. Paelinck B, Vermeersch P, Stockman D, et al. Usefulness of low-dose dobutamine stress echocardiography in predicting recovery of poor left ventricular function in atrial fibrillation dilated cardiomyopathy. Am J Cardiol 1999; 83(12): 1668–71

    PubMed  Article  CAS  Google Scholar 

  56. Khand AU, Cleland JG, Deedwania PC. Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Fail Rev 2002; 7(3): 267–83

    PubMed  Article  CAS  Google Scholar 

  57. Van den Berg MP, Tuinenburg AE, van Veldhuisen DJ, et al. Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. Int J Cardiol 1998; 63(1): 63–70

    PubMed  Article  Google Scholar 

  58. Agarwal AK, Venugopalan P. Beneficial effects of carvedilol on heart rate response to exercise in digitalized patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. Eur J Heart Fail 2001; 3(4): 437–40

    PubMed  Article  CAS  Google Scholar 

  59. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142(3): 498–501

    PubMed  Article  CAS  Google Scholar 

  60. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38(7): 2101–13

    PubMed  Article  CAS  Google Scholar 

  61. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103(10): 1428–33

    PubMed  Article  CAS  Google Scholar 

  62. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334(21): 1349–55

    PubMed  Article  CAS  Google Scholar 

  63. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and WIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 1998; 98(10): 953–60

    PubMed  Article  CAS  Google Scholar 

  64. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344(12): 873–80

    PubMed  Article  CAS  Google Scholar 

  65. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346(24): 1845–53

    PubMed  Article  Google Scholar 

  66. Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol 2002; 39(2): 194–201

    PubMed  Article  Google Scholar 

  67. Leclercq C, Victor F, Alonso C, et al. Comparative effects of permanent biventricular pacing for refractory heart failure in patients with stable sinus rhythm or chronic atrial fibrillation. Am J Cardiol 2000; 85(9): 1154–6

    PubMed  Article  CAS  Google Scholar 

  68. Lupi G, Brignole M, Oddone D, et al. Effects of left ventricular pacing on cardiac performance and on quality of life in patients with drug refractory heart failure. Am J Cardiol 2000; 86(11): 1267–70

    PubMed  Article  CAS  Google Scholar 

  69. Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23(22): 1780–7

    PubMed  Article  CAS  Google Scholar 

  70. Bubien RS, Knotts-Dolson SM, Plumb VJ, et al. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996; 94(7): 1585–91

    PubMed  Article  CAS  Google Scholar 

  71. Dorian P, Jung W, Newman D, et al. The impairment of healthrelated quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36(4): 1303–9

    PubMed  Article  CAS  Google Scholar 

  72. Savelieva I, Paquette M, Dorian P, et al. Quality of life in patients with silent atrial fibrillation. Heart 2001; 85(2): 216–7

    PubMed  Article  CAS  Google Scholar 

  73. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation; Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356(9244): 1789–94

    PubMed  Article  CAS  Google Scholar 

  74. Wise DG, Waldo AL, Di Marco JP, et al. A comparison of rate control anf rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–33

    Article  Google Scholar 

  75. Coletta A, Thackray S, Nikitin N, et al. Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail 2002; 4(3): 381–8

    PubMed  Article  Google Scholar 

  76. Louis A, Cleland JG, Crabbe S, et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure: highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3(3): 381–7

    PubMed  Article  CAS  Google Scholar 

  77. Carlsson J, Micus S, Haun S, et al. Quality of life in patients with atrial fibrillation: rate versus rhythm control [abstract]. Pacing Clin Electrophysiol 2002; 25(4): 565

    Google Scholar 

  78. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344(14): 1043–51

    PubMed  Article  CAS  Google Scholar 

  79. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834–40

    PubMed  Article  Google Scholar 

  80. Piot O, Chauvel C, Lazarus A, et al. Effects of a selective Al-adenosine receptor agonist on heart rate and heart rate variability during permanent atrial fibrillation. Pacing Clin Electrophysiol 1998; 21(11 Pt 2): 2459–64

    PubMed  Article  CAS  Google Scholar 

  81. Schauerte P, Scherlag BJ, Patterson E, et al. Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system. J Cardiovasc Electrophysiol 2001; 12(5): 592–9

    PubMed  Article  CAS  Google Scholar 

  82. Waninger MS, Bourland JD, Geddes LA, et al. Electrophysiological control of ventricular rate during atrial fibrillation. Pacing Clin Electrophysiol 2000; 23(8): 1239–44

    PubMed  Article  CAS  Google Scholar 

  83. Donahue JK, Heldman AW, Fraser H, et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med 2000; 6(12): 1395–8

    PubMed  Article  CAS  Google Scholar 

  84. Blitzer M, Costeas C, Kassotis J, et al. Rhythm management in atrial fibrillation: with a primary emphasis on pharmacological therapy: Part 1. Pacing Clin Electrophysiol 1998; 21(3): 590–602

    PubMed  Article  CAS  Google Scholar 

  85. Roden DM, Nadeau JH, Primm RK. Electrophysiologic and hemodynamic effects of chronic oral therapy with the alpha 2-agonists clonidine and tiamenidine in hypertensive volunteers. Clin Pharmacol Ther 1988; 43(6): 648–54

    PubMed  Article  CAS  Google Scholar 

  86. Roth A, Kaluski E, Feiner S, et al. Clonidine for patients with rapid atrial fibrillation. Ann Intern Med 1992; 116(5): 388–90

    PubMed  CAS  Google Scholar 

  87. Simpson CS, Ghali WA, Sanfilippo AJ, et al. Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial. Am Heart J 2001; 142(2): E3

    PubMed  Article  CAS  Google Scholar 

  88. Scardi S, Humar F, Pandullo C, et al. Oral clonidine for heart rate control in chronic atrial fibrillation. Lancet 1993; 341(8854): 1211–2

    PubMed  Article  CAS  Google Scholar 

  89. Camm AJ, Savelieva I. Rate versus rhythm control: is the debate over? J Interv Card Electrophysiol 2002; 7(1): 7–11

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

We are grateful to our librarian Claudia Cavicchi for constant bibliographic assistance, and to Robin MT Cooke for scientific editing. No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Affiliations

  1. Institute of Cardiology, University of Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti 9, 40138, Bologna, Italy

    Giuseppe Boriani, Mauro Biffi, Igor Diemberger, Cristian Martignani & Angelo Branzi

Authors
  1. Giuseppe Boriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mauro Biffi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Igor Diemberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cristian Martignani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Angelo Branzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Boriani.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Boriani, G., Biffi, M., Diemberger, I. et al. Rate Control in Atrial Fibrillation. Drugs 63, 1489–1509 (2003). https://doi.org/10.2165/00003495-200363140-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363140-00005

Keywords

  • Atrial Fibrillation
  • Digoxin
  • Amiodarone
  • Carvedilol
  • Calcium Channel Antagonist